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The function of pulmonary surfactant of a group of 14 preterm neonates (birth
weight 907 B 60 g) who suffered from severe respiratory distress syndrome
(RDS) and who had received exogenous bovine lipid extracted surfactant on
the first day of life was compared to that in a second group of 8 neo-
nates (birth weight 940 B 110 g) with mild RDS who had not received surfac-
tant treatment. Mechanical respiratory support from day 2 on was the same in
both groups. The minimal surface tension (Ámin) improved steadily, falling
from about 30 mN/m initially to less than 20 mN/m before extubation. A
consistent but loose correlation was found between Ámin and mechanical respi-
ratory support necessary, as quantitated by the oxygenation index. Total pro-
tein was about 0.8 B 0.2 mg/mg of phospholipids and did not change during
the first week of life. There were no correlations between total protein and Ámin
or the oxygenation index. The data suggest that inhibition of surfactant func-
tion by proteins leaked into the airspaces does not play a major role during
recovery from RDS. Instead, endogenous remodelling of surfactant might be
of greater relevance.
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Introduction
Avery and Mead [1] were the first to propose that lung
extracts from very small premature infants had a higher
than expected surface tension, indicating that their surfac-
tant is deficient. It has also been reported that in the
sequential airway samples of infants with respiratory dis-
tress syndrome (RDS) who had not received exogenous
surfactant treatment, the minimim surface tension (Ámin)
fell steadily from about 28 mN/m to values less than 10
mN/m at the time of extubation [2]. In a more recent
investigation, no differences in Ámin between postnatal
day 1 and days 2–4 were observed [3]. While surfactant
substitution is now an established and essential element
in the care of the preterm neonate with RDS, relatively
little is known about surfactant function in human neo-
nates during the course of RDS, especially regarding the
effect of exogenous surfactant administration. Such bio-
physical data would be a useful basis for understanding
how this mode of therapy could be optimised. Several
reports on the changes of biochemical parameters in the
airway secretions, like the phospholipid composition [3–
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5], the surfactant proteins present [3–6] and pharmakoki-
netics of surfactant [7–9] suggest that substantial rearran-
gements in the pulmonary surfactant system take place
following exogenous surfactant replacement therapy. In
addition, surfactant dysfunction due to the leakage of
plasma proteins into the airspaces [10] may severely affect
surfactant function [11, 12]. Whether exogenous surfac-
tant substitution reduces protein leakage, as estimated by
reduced protein contents in lavages, or whether it corrects
the function of a primarily impaired surfactant, is not yet
clear. The aim of this study, therefore, was to investigate
the surfactant function of sequential small-volume la-
vages in neonates with RDS who had received a bovine
natural surfactant in comparison to neonates who had not
received an exogenous surfactant.
Materials and Methods
The study was approved by the authorised Human Research Com-
mittee of our university and informed consent from the parents or
guardians was obtained. Tracheobronchial small-volume lavages of 22
infants less than 30 weeks of gestation who were ventilated from post-
natal day 1 to day 7 were collected. The diagnosis of RDS was estab-
lished clinically and by typical chest radiograph appearance, in the
absence of other causes for respiratory distress like infection, sepsis,
cardiac defects or congenital malformations. Surfactant was adminis-
tered on the first day of life as a bolus through the endotracheal tube
when the inspiratory oxygen fraction (FiO2) was greater than 0.4 or the
peak inspiratory pressure was higher than 20 cm H2O (196 Pa) for
infants less than 27 weeks of gestation or 22 cm H2O (216 Pa) for
infants older than 27 weeks, respectively. After the procedure, the neo-
nates were immediately reconnected to the ventilator at pretreatment
settings. On average, a dose of 83 B 6 mg/kg body weight of the lipid
extracted bovine surfactants Alveofact (Thomae, Biberach, Germany)
or Survanta (Abbott, Wiesbaden, Germany) were given. Fourteen neo-
nates had to be treated with surfactant, 1 infant received three doses,
1 two doses, the others a single dose. In infants receiving no surfactant
(n = 8), no placebo was used. The mode of ventilation during the study
period was standardised, with inspiratory time in the range of 0.2–
0.4 s, initial respiratory rates of 60–80/min, and positive endexspira-
tory pressure at 3 cm H2O (29 Pa). Ventilatory pressure support was
adjusted, so that the arterial oxygen partial pressure was in the range of
50–70 mm Hg (6.6–9.3 kPa), oxygen saturation was more than 90%
and the carbon dioxide partial pressure in blood was between 40 and
50 mm Hg (5.3 and 6.6 kPa). Postductal arterial blood gases were
drawn every 3–6 h. The oxygenation index (MAP ! FiO2/PaO2) was
calculated as described previously [9].
The small-volume lavages of the nasotracheally intubated neo-
nates were routinely obtained by lavage with 1 ml/kg body weight of
0.45% saline injected through the endotracheal tube and recovered
through a suction catheter into a Leuken trap. This material was gent-
ly vortexed for 1 min and centrifuged at 150 g at 4°C for 10 min. The
supernatant was recovered and stored at –80°C. From an aliquot,
the lipids were extracted and total amounts of phospholipids deter-
mined [9]. The sample was concentrated in a centrifuge under
reduced pressure. Surface activity of the samples was measured at
a final phospholipid concentration of 1 mmol/l. One aliquot was
directly used (native), a second was substituted with CaCl2 (3 mM )
and third aliquot was substituted with 5 mM ethylenediaminetetra-
acetic acid (EDTA). Surface tension was recorded in a pulsating bub-
ble surfactometer (Electronetics, Amherst, Mass., USA) during static
conditions after 12 s (adsorption), and Ámin was read after 3 min of
pulsations, while the radius of the bubble oscillated from 0.55 to
0.40 mm (corresponding to 50% surface compression) at a rate of 20
oscillations/min [13].
Total protein was determined with Coomassie Brilliant Blue G-
250 (Bio Rad, Munich, Germany) according to Bradford [14].
Statistical evaluation was performed on Graphpad software pack-
ages (San Diego, Calif., USA). Linear correlation analysis was per-
formed, and coefficients of correlation were tested according to Sachs
[15]. The two groups were compared by the unpaired t test. The level
of significance was set at p ! 0.05. First, infants receiving either of the
two surfactant preparations Alveofact (n = 9) or Survanta (n = 5)
were separately analysed, and no differences for gestational age, birth
weight, changes in Ámin and protein content were observed. There-
fore, in further analyses, these infants were treated as a single group
having received surfactant. The data were expressed as means B
SEM from n different subjects investigated.
Results
Two groups of neonates, with and without surfactant
treatment, did not differ in gestational age (26.2 B 0.4 vs.
27.3 B 0.6 weeks), birth weight (907 B 60 vs. 940 B
110 g), prenatal corticosteroids (38 vs. 42%), Apgar
scores, the rate of cesarean section (75% vs. 80%) and
socio-economical background. In accordance with the
study design, at about 3.9 h of life, the average time of
surfactant treatment, FiO2 and respiratory support were
higher in infants that required surfactant therapy (fig. 1).
In the case of exogenous surfactant therapy, the respirato-
ry support necessary dropped rapidly (fig. 1). In agree-
ment with previous studies [16, 17], no differences be-
tween the two bovine surfactant preparations used were
noted, and therefore, the data were reported for the group
of surfactant-treated neonates as a whole. During the fol-
lowing 6 days, no differences in respiratory support neces-
sary were observed between this group of surfactant-
treated neonates and the neonates not treated with exoge-
nous surfactant (fig. 1). The time of extubation was the
same in both groups. At 28 days of life, about half of the
neonates in each group still needed oxygen or mechanical
ventilation, and they had x-ray changes which were char-
acteristic of bronchopulmonary dysplasia.
The phospholipid mass recovered during the first week
of life was consistently lower in neonates with RDS and
surfactant treatment (table 1). To assess the surfactant
activity of the material recovered and to compare differ-
No surfactant
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Fig. 1. Respiratory support necessary during the first week of life
was quantiated by the oxygenation index in premature neonates with
the RDS. On average, surfactant was given 3.9 h after birth. Values
are means B SEM. [ = Data of 8 neonates with time after birth that
did not receive exogenous surfactant; P = data from 14 neonates
with time after surfactant therapy.
Fig. 2. Time course of Ámin of surfactant isolated from the small-
volume lavages of neonates with RDS without (a) and with treatment
with a bovine surfactant (b). Individual values of each neonate
(represented by a particular symbol) and the linear regression line for
all values are given.
Table 1. Phospholipid mass recovered on average in small-volume lavages during the first week of life in prema-
ture infants with RDS with or without surfactant therapy
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
855B435 1,016B382 752B179 599B65** 453B76* 465B153 800B331*
Surfactant 708B166 582B142 481B103 316B50 244B53 295B30 256B62
Data are expressed as nmol phospholipid/sample recovered and are means B SEM of 8 infants receiving no
surfactant treatment and of 14 neonates receiving surfactant. * p ! 0.05, ** p ! 0.01 by the unpaired t test.
1
2
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ent small-volume lavages, measurements were made at a
fixed phospholipid concentration. The minimum surface
tension was initially about 30 mN/m and fell on average
linearly with time. However, as there was a substantial
variation, the individual values are given (fig. 2). No dif-
ferences were noted between neonates treated with exoge-
nous surfactant and those without treatment. In both
groups, the addition of calcium significantly improved
surface tension (table 2), whereas a deterioration was
noted with calcium chelation by EDTA (table 2).
The adsorption to an air-liquid was estimated from
surface tension data of the non-pulsating bubble after
12 s. No changes with time or differences between the two
groups were found (with surfactant treatment Áads = 47 B
0.7 vs. 49 B 0.5 mN/m in neonates without surfactant
treatment). The total content of protein was the same in
both groups, i.e. about 0.8 B 0.2 mg/mg phospholipid,
and did not change with time (data not shown).
The respiratory support which was necessary for ap-
propriate oxygenation and ventilation was quantitated by
the oxygenation index. Consistent correlations were
found with Ámin (fig. 3). Although the correlations were
Fig. 3. Correlation between oxygenation index and Ámin of the
small-volume lavages of neonates with RDS. These infants were
treated without (a) or with a bovine surfactant (b). Individual values
of each neonate (represented by a particular symbol), the linear
regression line and the results of correlation analysis are given.





native Ca2+ 3 mM EDTA 5 mM
No surfactant
native Ca2+ 3 mM EDTA 5 mM
29.3B1.7 22.6B1.9 31.9B2.1 30.1B1.4 25.6B2.6 32.7B1.6
2 28.7B1.5 24.7B2.1 32.9B2.0 26.5B2.1 23.6B2.4 29.5B2.0
3 25.5B1.6 22.3B1.7 31.3B1.9 23.1B1.4 19.6B1.8 25.2B1.9
4 21.8B2.0 18.2B1.5 22.5B2.5 25.9B1.9 23.5B2.3 29.9B1.8
5 22.1B1.6 18.5B2.1 25.3B3.0 24.1B1.9 19.0B2.2 27.1B2.1
6 19.1B1.8 18.2B2.7 21.3B5.9 24.6B2.0 17.7B1.2 25.2B2.4
7 19.1B2.1 16.8B2.5 25.0B4.2 20.5B2.0 18.4B2.9 23.2B2.4
Data are means B SEM from 14 surfactant-treated neonates and 8 neonates not treated with surfactant.
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Fig. 4. Correlation between protein content and Ámin of small-
volume lavages from premature neonates with RDS. These infants
were treated without (a) or with a bovine surfactant (b). Individual
values of each neonate represented by a particular symbol are given.
No correlation was observed.
not very tight, they indicated that the better the surface
activity, e.g. the lower Ámin, the less mechanical respirato-
ry support was needed. In contrast, no correlation was
found either between the protein content and Ámin (fig. 4)
or between the protein content and the oxygenation index
(data not shown). All these findings held consistently for
both groups of neonates, also when the FiO2 or the venti-
lation index (peak inspiratory pressure ! respiratory rate)
were used instead of the oxygenation index (data not
shown).
Discussion
We studied the functional properties of the lung surfac-
tant system in very low birth weight premature infants
with RDS. One group of neonates received exogenous sur-
factant therapy for severe RDS. The mechanical respira-
tory support which was then necessary as quantitated by
the oxygenation index did not differ from that of the
group without surfactant treatment. So, all neonates lev-
elled off on day 2 with a mild form of RDS. It is not clear
whether a deficiency in surfactant mass was still present
in both groups or not. The somewhat lower phospholipid
total mass recovered in the small-volume lavages made
this more likely for surfactant-treated infants (table 1).
This issue could only be resolved by measuring total lung
surfactant content, which is not feasable in humans, or
clinically by the effect of a repeated administration of sur-
factant for very mild RDS beyond day 1 of life. Speer et
al. [18] have demonstrated beneficial effects of repeated
dosages of exogenous surfactant for infants with severe
RDS, whereas this has not yet been demonstrated in very
mild RDS.
The primary goal of this study was to assess the quality
of surfactant, but not its mass. This was achieved by nor-
malising measurement conditions to a fixed phospholipid
concentration of 1 mmol/l. This value was chosen since a
concentration dependency up to 0.5 mmol/l, but not above,
has been observed [unpubl. data; see also ref. 2]. On aver-
age, Ámin was relatively high on the first day of life and
linearly decreased to lower but not normal (e.g. 10 mN/m)
values. Such a steady improvement was seen in most
infants. The substantial variation over time may be con-
nected with sampling from variable sites in the lungs [19],
inhomogeneous lung injury or problems with the assess-
ment of surface tension in the pulsating bubble surfactom-
eter. The latter is unlikely, as daily quality control measure-
ments of aliquotted surfactants showed coefficients of vari-
ation less than 5%. Additionally, repeated measurements
of the same samples and measurements in the presence or
absence of EDTA and calcium were close in range.
In both groups of neonates with and without exogenous
surfactant treatment, a steady improvement of surfactant
functional properties was observed. These changes corre-
lated with the reduced need for mechanical respiratory
support. While such a correlation appears evident, the
factors that determine these changes in biophysical activi-
ty are much less clear.
Based on the studies of Jefferies et al. [10], which had
shown an impaired alveolar-capillary barrier in neonates,
we had anticipated substantial leakage of plasma proteins
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into the air space. Evidence supporting some role of sur-
factant inhibition may be derived from the enhancing
effects of the additional calcium (table 2), which may
indicate inhibition by serum [20]. On the first and second
days of life, the effect of in vitro addition of calcium was
about twice as great as later, when chelation of Ca2+ ions
with EDTA was more pronounced. Some studies indi-
cated that in animals, a ratio between proteins and phos-
pholipid above 1 results in the impairment of surfactant
function [11, 21]; if our neonates had higher ratios, we did
not fractionate the small-volume lavages into a surfac-
tant-rich fraction (which may be more relevant for func-
tion) and a supernatant fraction. Our previous data sug-
gest that only a minority (about 10%) of the total protein
would localise in the surface-active fraction [22]. Other
arguments against the inhibition of surfactant as being
the major mechanism of surfactant dysfunction in these
infants are the consistent lack of correlation between
protein content and the oxygenation index or Ámin. No
changes over time were observed, and there was no differ-
ence between surfactant-treated infants and those who
had not received treatment, especially during the first day
of life. This data is consistent with data in pre-term venti-
lated lambs [23]. The fact that about 50–60% of the pro-
tein recovered was albumin and that this fraction was
very constant (data not shown) makes it likely that plasma
is the source of the protein. Taken together, our measure-
ments of total protein do not explain the observed
changes in Ámin. But one has to keep in mind that bidirec-
tional fluxes of proteins and possibly specific inhibitory
proteins which may only represent less than 10% of the
protein mass [2] might play some role. As the assessment
of the biophysical activity of surfactant was the primary
goal, other potential inhibitors such as amino acids [4] or
changes in neutral lipids and cholesterol [24] remained
undetermined. In the same way, due to lack of material,
protecting factors like the surfactant proteins A, B and C
[5] could also not be measured directly in this study. In
comparable neonates, we had previously found no evi-
dence for changes of dipalmitoyl-phosphatidylcholine
content, the principal phospholipid of surfactant, during
the first week of life. However, substantial changes in oth-
er phospholipids [9] indicated that lung metabolic pro-
cesses may continuously modify endogenous and exoge-
nous surfactant composition and properties [25].
To conclude briefly, exogenous surfactant administra-
tion almost instantaneously ameliorated severe RDS.
During the first week of life that followed with mild RDS,
the functional properties of surfactant obtained with
small-volume lavages steadily improved, and no differ-
ences to comparable premature infants who did not
receive surfactant were observed. These data suggest that
not the removal of leaked proteins, which might act as
inhibitors of surfactant function, plays the predominant
role during the recovery of RDS, but that the endogenous
metabolism possibly improved surfactant functions.
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